Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties

Medical Hypotheses

Volumn 62, Issue 6, 2004, Pages 942-944

  Aksoy, Sercan ^a   Abali, Huseyin ^a   Dinçer, Murat ^a   Kilickap, Saadettin ^a   Güllü, Ibrahim ^a   Tekuzman, Gülten ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BONE METASTASIS; CALCIUM METABOLISM; CALCIUM SIGNALING; CALCIUM TRANSPORT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOTHESIS; MITOGENESIS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SHORT SURVEY; SYMPTOMATOLOGY; VITAMIN SUPPLEMENTATION;

EID: 2542444576     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.001     Document Type: Article

References (17)

1. Green JR. Anti-tumor potential of bisphosphonates. Med Klin 2000;2(Suppl 95):23-8.
2. Berridge MJ. Calcium signalling and cell proliferation. Bioessays 1995;17:491-500.
3. Solthoff SP, Cantley LC. Mitogens and ion fluxes. Ann Rev Physiol 1988;50:207-23.
4. Nilius B, Viana F, Droogmans G. Ion channels invascular endothelium. Ann Rev Physiol 1997;59:145-70.
5. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
6. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002;29:33-42.
7. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002;25:3-9.
8. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4.
9. Santini D, Vespasiani GU, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468-76.
10. Abali H, Altundag MK, Baltali E, Oral D, Canpinar H, Guc D, et al. Does zoledronic acid decrease serum levels of basic fibroblast growth factor and vascular endothelial growth factor? Proc Am Soc Clin Oncol 2003;22:215 (abstr 862).
11. Zimering MB. Effect of intravenous bisphosphonates on release of basic fibroblast growth factor in serum of patients with cancer-associated hypercalcemia. Life Sci 2002;70:1947-60.
12. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7.
13. Oliver VK, Patton AM, Desai S, Lorang D, Libutti SK, Kohn EC. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. J Cell Physiol 2003;197:139-48.
14. Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, et al. Phase II trial of carboxyamidotriazole in patients with elapsed epithelial ovarian cancer. J Clin Oncol 2003;21:4356-63.
15. Patton AM, Kassis J, Doong H, Kohn EC. Calcium as a molecular target in angiogenesis. Curr Pharm Des 2003;9: 543-51.
16. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557-61.
17. Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control 2002;9:480-9.